Individualized commercial formulation reduces diarrhea in adult ICU patients receiving tube-fed enteral nutrition.
This retrospective cohort study evaluated 605 adult ICU patients receiving tube-fed enteral nutrition at Henan Provincial People's Hospital. The analysis compared an individualized commercial formulation (ICF) against standard commercial enteral nutrition (CEN). The primary outcome assessed was the incidence of diarrhea, while secondary outcomes included feeding interruption, gastric residual volume, constipation, hyperglycemia, and composite gastrointestinal complications.
Results indicated a lower incidence of diarrhea in the ICF group compared to the CEN group, with absolute rates of 13.6% versus 41.5%. The adjusted odds ratio was 0.27 (95% CI 0.11–0.68; p = 0.005). Additionally, fewer feeding interruptions occurred in the ICF group compared to the CEN group, with an incidence rate ratio of 0.29 (95% CI 0.18–0.45; p = 0.005). Data for other secondary outcomes were not reported in the provided text.
The study did not report specific adverse events, serious adverse events, discontinuations, or detailed tolerability metrics. As an observational study, causal inferences cannot be made. The findings suggest a potential benefit of ICF regarding gastrointestinal complications, but the retrospective nature and lack of randomization limit the certainty of these results. Clinicians should interpret these associations cautiously until supported by higher-quality evidence.